Delving into the Latest Updates on Human cord derived MSC cell(Shanghai Aisar Biotechnology) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

IxCell hUC-MSC-O, IxCell hUC-MSC-P, IxCell hUC-MSC-S

Target-

Action-

Mechanism

Stem cell replacements

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesNervous System Diseases+ [2]

Active Indication

Osteoarthritis, KneeIschemic strokeInterstitial lung disease due to connective tissue disease+ [1]

Inactive Indication-

Originator Organization

IxCell Biotechnology Co., Ltd.

Active Organization

IxCell Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to evaluate the efficacy, safety, and pharmacodynamic characteristics of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in adults with ischemic stroke in the anterior circulation during the recovery phase. Researchers will compare hUC-MSCs to a placebo to determine whether hUC-MSCs treatment is effective in treating recovery-phase anterior circulation ischemic stroke.

Start Date01 Oct 2025

Sponsor / Collaborator

IxCell Biotechnology Co., Ltd.

NCT06823063

/ Not yet recruitingPhase 1

A Phase I Clinical Trial to Evaluate the Safety and Tolerability of a Single Dose of Human Umbilical Cord Mesenchymal Stem Cell Injection (IxCell hUC-MSC-P) in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

To evaluate the safety and tolerability of IxCell hUC-MSC-P in the treatment of patients with connective tissue disease-related interstitial lung disease.
To evaluate the efficacy, pharmacokinetics and immunogenicity of IxCell hUC-MSC-P in the treatment of connective tissue disease-associated interstitial lung disease (CTD-ILD).

Start Date01 Apr 2025

Sponsor / Collaborator

IxCell Biotechnology Co., Ltd.

NCT06716281

/ RecruitingPhase 3

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

To evaluate the efficacy of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis.
To evaluate the safety of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis.

Start Date05 Jan 2024

Sponsor / Collaborator

IxCell Biotechnology Co., Ltd.

100 Clinical Results associated with Human cord derived MSC cell(Shanghai Aisar Biotechnology)

Login to view more data

100 Translational Medicine associated with Human cord derived MSC cell(Shanghai Aisar Biotechnology)

Login to view more data

100 Patents (Medical) associated with Human cord derived MSC cell(Shanghai Aisar Biotechnology)

Login to view more data

100 Deals associated with Human cord derived MSC cell(Shanghai Aisar Biotechnology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 3	China	IxCell Biotechnology Co., Ltd.	05 Jan 2024
Ischemic stroke	Phase 2	China	IxCell Biotechnology Co., Ltd.	01 Oct 2025
Interstitial lung disease due to connective tissue disease	Phase 1	China	IxCell Biotechnology Co., Ltd.	01 Apr 2025
Pulmonary Fibrosis	Phase 1	China	IxCell Biotechnology Co., Ltd.	-